ACIP Recommends MSD’s Enflonsia for Infants Under 8 Months to Prevent RSV
US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) revealed that the Advisory Committee...
Viatris Announces Positive Results in VEGA-3 Trial for MR-141 Presbyopia Treatment
US-based Viatris (NASDAQ: VTRS) announced positive topline results from the second pivotal Phase III VEGA-3...
Jenscare’s LuX-Valve Plus Shows Promising Results in Global TRINITY Study
Ningbo-based structural heart disease device maker Jenscare Scientific Co., Ltd (HKG: 9877) announced positive 30-day...
Innovent Biologics’ Mazdutide Gets NMPA Nod for Weight Management
China’s National Medical Products Administration (NMPA) has approved Innovent Biologics, Inc.’s (HKG: 1801) mazdutide (IBI362),...
Mabwell Bioscience Partners With Calico Life Sciences on 9MW3811 Development
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) is set to enter into a licensing...
China Raises Subsidy for Basic Public Health Services, Targets Vulnerable Groups
China’s National Health Commission (NHC) released the “Notice on Improving Basic Public Health Services in...
Hua Dong Medicine’s HDM2020 Gains NMPA Approval for Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Cutia Therapeutics’ Phase III Results for Lidocaine-Tetracaine Cream to be Presented at CSD Meeting
Cutia Therapeutics (HKG: 2487), a dermatology specialist, is set to present the Phase III clinical...
Novartis Completes Acquisition of Regulus Therapeutics for ADPKD Treatment
Swiss giant Novartis (NYSE: NVS) announced the completion of its acquisition of U.S.-based Regulus Therapeutics....
Sino Biopharmaceutical’s LM-108 Gains CDE BTD for Gastric Adenocarcinoma
Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has obtained Breakthrough Therapy Designation (BTD) from...
Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with compatriot firm...
Fosun Pharma’s Serplulimab Approved for ES-SCLC in the UK and India
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that its subsidiary Shanghai...
Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment
France-based major Sanofi (NASDAQ: SNY) has secured Orphan Drug Designation (ODD) from the US Food...
Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced the successful first patient dosing in its Phase III...
AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit
UK major AstraZeneca (AZ, NASDAQ: AZN) this week reportedly unveiled a new organizational restructuring plan,...
EMA Panel Recommends Brukinsa Tablet Formulation for Approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National...
CARsgen’s Satri-cel NDA Accepted by China’s NMPA for Gastric Adenocarcinoma
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the National Medical Products Administration (NMPA)...
Lepu Biopharma Gains EMA Approval for MRG003 HNSCC Clinical Trial
China-based Lepu Biopharma Co., Ltd (HKG: 2157) announced that it has received approval from the...
RemeGen Inks Global Licensing Pact With Vor Biopharma for Telitacicept
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an exclusive licensing agreement with U.S.-based...